BiotechTube

Lenvatinib + Pembrolizumab

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenoid Cystic Carcinoma

Conditions

Adenoid Cystic Carcinoma, Salivary Gland Cancer

Trial Timeline

Jun 2, 2020 → Dec 1, 2026

NCT ID
NCT04209660

About Lenvatinib + Pembrolizumab

Lenvatinib + Pembrolizumab is a phase 2 stage product being developed by Eisai for Adenoid Cystic Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04209660. Target conditions include Adenoid Cystic Carcinoma, Salivary Gland Cancer.

What happened to similar drugs?

1 of 2 similar drugs in Adenoid Cystic Carcinoma were approved

Approved (1) Terminated (0) Active (1)
✅mometasone furoate nasal sprayOrganonApproved
🔄Mometasone Furoate nasal spray + PlaceboOrganonPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT04645602Phase 1Recruiting
NCT04209660Phase 2Active
NCT03776136Phase 2Completed
NCT03609359Phase 2Completed
NCT03006887Phase 1Completed
NCT02501096Phase 1/2Completed

Competing Products

11 competing products in Adenoid Cystic Carcinoma

See all competitors
ProductCompanyStageHype Score
Enfortumab VedotinAstellas PharmaPhase 2
42
LenvatinibEisaiPhase 2
39
P-SamAstraZenecaPhase 2
42
CetuximabMerckPhase 1/2
28
PembrolizumabMerckPhase 2
35
DovitinibNovartisPhase 2
35
Dovitinib (TKI258)NovartisPhase 2
35
AG-013736 (AXITINIB)PfizerPhase 2
35
RegorafenibBayerPhase 2
32
Mometasone Furoate nasal spray + PlaceboOrganonPhase 3
34
mometasone furoate nasal sprayOrganonApproved
37